Shots:
- Dyno Therapeutics has reported that Astellas has exercised its option to license an AI-engineered AAV capsid for skeletal muscle delivery, marking the first licensed asset from their 2021 collaboration
- The capsid, designed using Dyno’s AI models trained on large-scale in vivo data, demonstrates improved muscle targeting at lower doses, addressing key safety & manufacturing challenges in gene therapy
- As per the deal, Astellas will pay $15M license fee & assume responsibility for preclinical, clinical, & commercialization activities, while Dyno remains eligible for milestone payments & royalties on resulting therapies
Ref: Businesswire | Image: Dyno & Astellas | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
